๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

10 recruiting trials

for Relapsing Multiple Sclerosis (RMS)

Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) Levels NCT07353216n/a1 site๐Ÿ“ Guangzhou Third Affiliated Hospital, Sun Yat-Sen University ยท Tests: Ofatumumab A Study Evaluating the Real World Experience of Participants Treated With BRIUMVIยฎ (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) NCT06433752n/a111 sites๐Ÿ“ Birmingham๐Ÿ“ Cullman๐Ÿ“ Huntsville TG Therapeutics, Inc. ยท Tests: No Intervention Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis NCT07220252Phase 2, Phase 33 sites๐Ÿ“ Gdansk๐Ÿ“ Poznan๐Ÿ“ Warsaw TG Therapeutics, Inc. ยท Tests: Ublituximab, Placebo, Placebo, Fingolimod Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. NCT06846281Phase 3131 sites๐Ÿ“ Scottsdale๐Ÿ“ Irvine๐Ÿ“ Washington D.C. Novartis Pharmaceuticals ยท Tests: Remibrutinib oral treatment, Ocrelizumab Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational Study NCT06486779n/a15 sites๐Ÿ“ Athens๐Ÿ“ Athens๐Ÿ“ Alexandroupoli Novartis Pharmaceuticals ยท Tests: Ofatumumab A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS) NCT07161258Phase 217 sites๐Ÿ“ Rosario๐Ÿ“ San Miguel de Tucumรกn๐Ÿ“ Brasรญlia Hoffmann-La Roche ยท Tests: Fenebrutinib A Single-Center Study to Characterize the Safety and Efficacy of Ublituximab in Older Adults With Relapsing Forms of Multiple Sclerosis (RMS) NCT06681623n/a1 site๐Ÿ“ Foxborough Neurology Center of New England P.C. ยท Tests: Ublituximab A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis NCT05344469n/a141 sites๐Ÿ“ Albstadt๐Ÿ“ Hettingen๐Ÿ“ Hettingen Novartis Pharmaceuticals ยท Tests: ofatumumab, glatiramer acetate, interferon ฮฒ1, teriflunomide, dimethyl fumarate (DMF) Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study NCT05809986n/a10 sites๐Ÿ“ Amadora๐Ÿ“ Guimarรฃes๐Ÿ“ Leiria Novartis Pharmaceuticals ยท Tests: Ofatumumab An Open-label Study of AZD0120 in Adults With Multiple Sclerosis NCT07224373Phase 119 sites๐Ÿ“ Tucson๐Ÿ“ Aurora๐Ÿ“ Washington D.C. AstraZeneca ยท Tests: AZD0120 - Regimen 1, AZD0120 - Regimen 2
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy